Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This study is a randomized controlled trial (RCT) comparing adjuvanted influenza vaccine (AV) to unadjuvanted inactivated influenza vaccine (IIV). Children in Hutterite colonies in Alberta and Saskatchewan will receive AV or IIV. The goal of this study is to determine whether the AV vaccine, can provide increased community-wide protection.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Months to 72 Months (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Group A: Receive Intervention
Healthy children aged 6 months to 72 months
Anaphylactic reaction to a previous dose of influenza vaccine or to any of its components
Known Immunoglobulin E (IgE)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock
Guillain- Barré syndrome within eight weeks of a previous influenza vaccine
Use of aspirin or salicylate- containing products within 30 days before enrollment